...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of applied toxicology >Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context.
【24h】

Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context.

机译：利用生物监测等同物将人生物监测数据解释公共健康风险背景。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Increasingly sensitive analytical tools allow measurement of trace concentrations of chemicals in human biological media in persons from the general population. Such data are being generated by biomonitoring programs conducted by the US Centers for Disease Control and other researchers. However, few screening tools are available for interpretation of such data in a health risk assessment context. This review describes the concept and implementation of Biomonitoring Equivalents (BEs), estimates of the concentration of a chemical or metabolite in a biological medium that is consistent with an existing exposure guidance value such as a tolerable daily intake or reference dose. The BE approach integrates available pharmacokinetic data to convert an existing exposure guidance value into an equivalent concentration in a biological medium. Key concepts regarding the derivation and communication of BE values resulting from an expert workshop held in 2007 are summarized. BE derivations for four case study chemicals (toluene, 2,4-dichlorophenoxyacetic acid, cadmium and acrylamide) are presented, and the interpretation of biomonitoring data for these chemicals is presented using the BE values. These case studies demonstrate that a range of pharmacokinetic data and approaches can be used to derive BE values; fully developed physiologically based pharmacokinetic models, while useful, are not required. The resulting screening level evaluation can be used to classify these compounds into relative categories of low, medium and high priority for risk assessment follow-up. Future challenges related to the derivation and use of BE values as tools in risk management are discussed.
机译：越来越敏感的分析工具允许在一般人群中的人体生物培养基中的痕量化学品测量。这些数据正在由美国疾病控制和其他研究人员进行的生物监测计划产生。但是，很少有筛选工具可用于解释健康风险评估环境中的这些数据。该综述描述了生物监测等同物（BES）的概念和实施，生物培养基中的化学或代谢物的浓度估计，其与现有的暴露引导值（例如可耐受的每日摄入或参考剂量）一致。该方法将可用的药代动力学数据集成，将现有的暴露引导值转换为生物培养基中的等同浓度。总结了2007年专家研讨会所产生的推导和沟通的关键概念。出现四个案例研究（甲苯，2,4-二氯苯乙烯酸，镉和丙烯酰胺）的衍生，并且使用BE值给出这些化学品的生物管数据的解释。这些案例研究表明，可以使用一系列药代动力学数据和方法来导出值;完全开发的生理基础的药代动力学模型，同时不需要。得到的筛选水平评估可用于将这些化合物分类为风险评估随访的低，中等和高优先级的相对类别。讨论了与风险管理工具的推导和使用具有衍生和使用的未来挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号